Argent Advisors’s Edwards Lifesciences EW Stock Holding History

Argent Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9	Closed	–	–	247
2019 Q4	$0	Buy	+9	New	+$703	﹤0.01%	514

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Argent Advisors's EW Position: Q1 2020 in Review

Argent Advisors sold out of Edwards Lifesciences (EW) in Q1 2020, closing a stake of 9 shares.

Argent Advisors first reported a position in EW in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 1,019 funds tracked by Wall St. Rank hold EW as of Q1 2020.

Argent Advisors reported no remaining Edwards Lifesciences position as of Q1 2020 after selling out during the quarter.
Argent Advisors sold 9 Edwards Lifesciences shares in Q1 2020.
Argent Advisors first reported a position in Edwards Lifesciences in Q4 2019 and held it in 1 quarter.
Argent Advisors's Edwards Lifesciences position peaked at $0 in Q4 2019.
1,019 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2020.

Based on Argent Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.